Immunogenicity of interferon-alpha 2 in therapy: structural and physiological aspects

Area of Science:

• Biochemistry
• Immunology
• Protein Engineering

Background:

• Recombinant human interferon (rIFN)-alpha 2 is used for oncological and viral diseases.
• Therapeutic efficacy can be limited by patient-specific antibody responses to rIFN-alpha 2.
• The humoral response to rIFN-alpha 2 is complex and multifactorial.

Purpose of the Study:

• To review factors contributing to the formation of therapy-induced antibodies against rIFN-alpha 2.
• To identify structural modifications of rIFN-alpha 2 critical for immunogenicity.
• To explore the impact of production and storage on rIFN-alpha 2 immunogenicity.

Main Methods:

• Literature review focusing on structural and immunogenic properties of rIFN-alpha 2.
• Analysis of factors influencing antibody response to recombinant proteins.
• Consideration of production, purification, and storage effects on protein structure and immunogenicity.

Main Results:

• Inherent conformational differences among IFN-alpha 2 subvariants can influence antibody formation.
• Immunogenic contaminants arising during production, purification, or storage are critical factors.
• Treatment regimens and host physiological variables modulate the immune response.

Conclusions:

• Structural characteristics of rIFN-alpha 2 play a significant role in inducing antibody responses.
• Understanding these factors is crucial for mitigating immunogenicity and optimizing therapeutic use.
• Further research into protein modifications and production processes can improve rIFN-alpha 2 therapy.